Literature DB >> 9054552

Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines.

M S Puvvada1, S A Forrow, J A Hartley, P Stephenson, I Gibson, T C Jenkins, D E Thurston.   

Abstract

The interactions of several pyrrolo[2, 1-c][1,4]benzodiazepine (PBD) antitumor antibiotics with linearized plasmid pGEM-2-N-ras DNA have been analyzed by quantitative in vitro transcription (QIVT) and in vitro transcription footprinting (IVTF) methods. A concentration-dependent inhibitory effect of the PBDs on transcription is observed using both techniques. The rank order for overall inhibition of transcription by the QIVT method is found to be: sibiromycin > tomaymycin > anthramycin > DC-81 > neothramycin, whereas the IVTF experiments show a different ranking: sibiromycin > anthramycin > neothramycin > tomaymycin. In addition, stimulation of transcription was observed at low PBD concentrations in both the QIVT and IVTF experiments. These results demonstrate unequivocally that the formation of PBD-DNA adducts at AGA-5' base sequences on the transcribed strand results in transcription blockage for all PBDs examined. Furthermore, the sequence of flanking base pairs appears to influence the degree of blocking, with the sequences ACAGAAA-5', AAAGATG-5', AGAGATA-5', and CAAGAAC-5' providing the most pronounced blocks for all PBDs studied in this system. Neothramycin and tomaymycin cause additional blocks at some GGA-5' and TGA-5' sequences. Parallel MPE-Fe(II) footprinting studies have revealed PBD binding sites on both the transcribing and nontranscribing strands, although all transcription blocks determined from the IVTF assays are due to drug bound on the transcribing DNA template strand.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9054552     DOI: 10.1021/bi952490r

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  Identification of the dioxygenase-generated intermediate formed during biosynthesis of the dihydropyrrole moiety common to anthramycin and sibiromycin.

Authors:  Shalini Saha; Wei Li; Barbara Gerratana; Steven E Rokita
Journal:  Bioorg Med Chem       Date:  2014-12-20       Impact factor: 3.641

Review 2.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

3.  Characterization of Interstrand DNA-DNA Cross-Links Derived from Abasic Sites Using Bacteriophage ϕ29 DNA Polymerase.

Authors:  Zhiyu Yang; Nathan E Price; Kevin M Johnson; Kent S Gates
Journal:  Biochemistry       Date:  2015-07-02       Impact factor: 3.162

Review 4.  Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines.

Authors:  Barbara Gerratana
Journal:  Med Res Rev       Date:  2010-06-13       Impact factor: 12.944

5.  DNA Sequence Preference and Adduct Orientation of Pyrrolo[2,1-c][1,4]benzodiazepine Antitumor Agents.

Authors:  Khondaker M Rahman; Higia Vassoler; Colin H James; David E Thurston
Journal:  ACS Med Chem Lett       Date:  2010-08-13       Impact factor: 4.345

6.  Processing of topoisomerase I cleavable complexes into DNA damage by transcription.

Authors:  J Wu; L F Liu
Journal:  Nucleic Acids Res       Date:  1997-11-01       Impact factor: 16.971

7.  Cloning and characterization of the biosynthetic gene cluster for tomaymycin, an SJG-136 monomeric analog.

Authors:  Wei Li; ShenChieh Chou; Ankush Khullar; Barbara Gerratana
Journal:  Appl Environ Microbiol       Date:  2009-03-06       Impact factor: 4.792

8.  Preliminary pharmacokinetic and bioanalytical studies of SJG-136 (NSC 694501), a sequence-selective pyrrolobenzodiazepine dimer DNA-cross-linking agent.

Authors:  Gary P Wilkinson; James P Taylor; Steve Shnyder; Patricia Cooper; Phil W Howard; David E Thurston; Terence C Jenkins; Paul M Loadman
Journal:  Invest New Drugs       Date:  2004-08       Impact factor: 3.850

9.  A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.

Authors:  Yelena Y Janjigian; Wooin Lee; Mark G Kris; Vincent A Miller; Lee M Krug; Christopher G Azzoli; Emir Senturk; M Wade Calcutt; Naiyer A Rizvi
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-12       Impact factor: 3.333

10.  Response of Staphylococcus aureus to subinhibitory concentrations of a sequence-selective, DNA minor groove cross-linking pyrrolobenzodiazepine dimer.

Authors:  Marie Doyle; Eva-Anne Feuerbaum; Keith R Fox; Jason Hinds; David E Thurston; Peter W Taylor
Journal:  J Antimicrob Chemother       Date:  2009-09-10       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.